Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Patient-derived organoid models of malignant phyllodes tumours for drug sensitivity testing and identification of targeted therapeutic strategies.

Journal of drug targeting - 1 Aug 2025

Chen Jie, Liu Liangquan, Yang Yunxu, Luo Jing, Liu Shengchun

Abstract excerpt

BACKGROUND: Malignant phyllodes tumours (MPT) of the breast are rare fibroepithelial neoplasms. It exhibits rapid growth, large size, and a high local recurrence rate. METHODS: In this study, we established novel patient-derived organoid (PDO) models from two primary MPT samples and conducted comprehensive genetic profiling and drug screening. RESULTS: The PDO models faithfully recapped the histopathological and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzimidazoles

Share to Drug Screening Assays, Antitumor

Share to High-Throughput Nucleotide Sequencing

Share to Molecular Targeted Therapy

Share to Organoids

Share to Precision Medicine

Source

Identifiers

PMID: 40059613
DOI: 10.1080/1061186X.2025.2473010

Genes

EGFR
RB1
ATM
RECQL4
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patient-derived organoid models of malignant phyllodes tumours for drug sensitivity testing and identification of targeted therapeutic strategies.PMID 40059613Read ↗

Morphologic and genetic heterogeneity in breast fibroepithelial lesions-a comprehensive mapping study.Semantic proximity Read ↗

The landscape of drug sensitivity and resistance in sarcomaSemantic proximity Read ↗

Patient-derived triple negative breast cancer organoids provide robust model systems that recapitulate tumor intrinsic characteristicsSemantic proximity Read ↗

Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities.Semantic proximity Read ↗

Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities.Semantic proximity Read ↗

Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapiesSemantic proximity Read ↗

Bladder cancer organoids as a functional system to model different disease stages and therapy responseSemantic proximity Read ↗

The landscape of drug sensitivity and resistance in sarcomaSemantic proximity Read ↗

Patient-derived urachal cancer organoids for personalized drug screeningSemantic proximity Read ↗

Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screeningSemantic proximity Read ↗

Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors.Semantic proximity Read ↗

Comprehensive genomic profiling of malignant phyllodes tumors of the breast.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.